Top Pfizer scientist discusses COVID-19 vaccine's efficacy and new variants
Pfizer announced it will supply 200 million doses of its COVID-19 vaccine for the U.S. by the end of May and is aiming to ship 2 billion doses globally this year. The vaccine is over 90% effective according to clinical trials conducted in 2020, but more testing needs to be done to see how well it protects against the new variants. Dr. Phil Dormitzer, who helped develop the vaccine as vice president and chief scientific officer of viral vaccines at Pfizer, joins CBSN to discuss.